Friday 6 November 2026
Export RXST’s income statement to Excel — free account
RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.
- Revenue
- −19.0%
- EPS
- −62.1%
- Free cash flow
- +2,591.1%
Quarter to September 2026, against a year earlier
4.57
0.03
+0.66%
Follow RXST
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 4 |
| (13.99%) | (17.06%) | (17.35%) | (20.10%) | ||
| (12.36%) | (15.12%) | (14.19%) | (16.44%) | ||
ROIC |
(63.34%) | (70.00%) | (63.16%) | (16,845.67%) | |
Return on Tangible Assets |
(14.20%) | (17.59%) | (17.99%) | (20.97%) | |
Average Days of Receivables |
63.47 | 64.26 | 224.64 | 50.93 | |
Free Cash Flow per Share |
(0.47) | (0.52) | (0.65) | 0.45 | |
Free Cash Flow |
(19.34) | (21.58) | (27.16) | 18.65 | |
Capital Expenditures |
(3.83) | (4.01) | (4.43) | (5.03) | |
| Other line items | |||||
Cash ROIC |
(3.84%) | (4.45%) | (5.75%) | 3.66% | |
Accounts Receivable Turnover |
5.03 | 4.77 | 2.39 | 5.92 | |
Accounts Payable Turnover |
6.40 | 4.12 | 5.92 | 8.55 | |
Inventory Turnover |
1.18 | 1.00 | 0.92 | 0.85 | |
Average Days of Payables |
61.42 | 88.75 | 80.67 | 42.96 | |
Days of Inventory on Hand |
366.03 | 434.39 | 471.93 | 496.94 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
28.67% | 29.54% | 28.75% | 30.23% | |
Selling, General and Administrative Expense of Revenue |
83.77% | 90.89% | 91.95% | 96.34% | |
Share Based Compensation of Revenue |
23.51% | 25.43% | 24.56% | 25.33% | |
Interest Coverage |
(2,536.37) | (3,459.12) | (3,936.64) | (4,727.15) | |
Operating CF/Net income |
0.40 | 0.38 | 0.48 | (0.44) | |
Depreciation/Fixed assets |
(0.40) | (0.35) | (0.29) | (0.24) | |
Capex/Depreciation |
0.73 | 0.86 | 1.10 | 1.43 | |
Revenue per Share |
3.29 | 3.09 | 3.07 | 2.92 | |
Operating CF per Share |
(0.38) | (0.43) | (0.55) | 0.57 | |
Capex per Share |
(0.09) | (0.10) | (0.11) | (0.12) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026